CRISPR — Editing the Code Itself

8.1: From Yogurt to Nobel Prize

In 1993, a Spanish microbiologist named Francisco Mojica was studying salt-loving archaea in the marshes of Alicante when he noticed something odd in their DNA: strange repetitive sequences, evenly spaced, with unique sequences between them. He puzzled over these for years, and in 2003 made a breakthrough. The unique sequences matched the DNA of viruses that had previously infected the archaea. The bacteria were keeping a genetic record of past infections, a molecular mugshot book. They were using these stored sequences to recognize and destroy returning viruses. Bacteria, it turned out, had an adaptive immune system. The repetitive sequences had been named CRISPR in 2002 — Clustered Regularly Interspaced Short Palindromic Repeats — but Mojica's breakthrough revealed what they actually did.

In 2012, Jennifer Doudna at UC Berkeley and Emmanuelle Charpentier at Umeå University and the University of Vienna published a landmark paper showing this bacterial defense system could be reprogrammed to edit DNA in any organism. The system uses two components. A guide RNA, a short sequence matching the DNA target, directs a protein called Cas9 to the exact genomic location where a cut should be made. Change the guide RNA, change the target. Molecular GPS plus molecular scissors. Feng Zhang at the Broad Institute demonstrated the following year that CRISPR-Cas9 could edit genes in human cells, opening the door to therapeutics.

In 2020, Doudna and Charpentier received the Nobel Prize in Chemistry, the fastest Nobel ever awarded for a biological tool, reflecting both the magnitude and the immediate practical impact. (A lengthy patent battle between UC Berkeley and the Broad Institute over CRISPR rights in eukaryotic cells was initially resolved in 2022 in the Broad Institute's favor, though appeals have continued.) CRISPR is now the most widely used gene-editing technology in the world, employed in thousands of laboratories and increasingly in clinical applications.

8.2: How It Works

The most intuitive way to understand CRISPR is as a molecular Find-and-Replace. You provide a guide RNA specifying the "Find" term, about twenty DNA letters matching the target gene. Cas9 scans the DNA, searching for a match. When it finds the target adjacent to a short motif called a PAM sequence (NGG, any nucleotide followed by two guanines), Cas9 cuts both strands of the DNA helix at that location. The cell attempts repair, and depending on the pathway, one of two things happens. If the cell uses error-prone "non-homologous end joining," the repair often introduces insertions or deletions that disrupt the gene, a knockout. If a template DNA sequence is provided, the cell can use "homology-directed repair" to insert a specific correction or new sequence.

The technology has evolved beyond cutting. David Liu's laboratory at Harvard developed base editors that chemically convert one DNA letter to another at a specific position without a double-strand break, like using correction fluid on a single letter rather than cutting a word from a sentence. Prime editing, from the same lab, can insert, delete, or replace short sequences without double-strand breaks and without a separate DNA template. These next-generation tools expand the range of safe, precise genetic corrections, addressing one of the main concerns about original CRISPR, the risk of unintended edits at off-target sites.

8.3: CRISPR in the Real World

On December 8, 2023, the FDA approved Casgevy (exagamglocel autotemcel), the first CRISPR-based therapy, for sickle cell disease. Sickle cell is caused by a single mutation in the hemoglobin gene that makes red blood cells rigid and crescent-shaped, blocking small blood vessels and causing excruciating pain episodes called vaso-occlusive crises. Casgevy edits the patient's own blood stem cells to reactivate fetal hemoglobin, a form normally active only during fetal development that compensates for the defective adult version. In trials, twenty-nine out of thirty patients (ninety-seven percent) were free of vaso-occlusive crises for at least twelve months. The cost is approximately two million dollars for a one-time treatment, but for a disease requiring a lifetime of hospitalizations, transfusions, and pain management, the economics are compelling.

CRISPR is also reaching beyond human medicine. Gene-edited crops with improved yields, disease resistance, and nutrition are in development, including non-browning mushrooms that received USDA clearance without the lengthy GMO regulatory process, since no foreign DNA is introduced. CRISPR-based diagnostics called SHERLOCK and DETECTR can detect specific viral or bacterial DNA in patient samples in thirty to sixty minutes at five to fifteen dollars, offering point-of-care testing for tuberculosis, Zika, and HPV in resource-limited settings.

But power demands vigilance. In November 2018, Chinese biophysicist He Jiankui announced he had used CRISPR to edit the CCR5 gene in human embryos, resulting in the birth of twin girls with modified genomes, the first gene-edited babies. The scientific response was nearly unanimously condemnatory. The edits were medically unnecessary (intended to confer HIV resistance), informed consent was inadequate, and the long-term consequences for the children and their potential offspring are unknown. He Jiankui was sentenced to three years in prison. The incident made a point that deserves repeating: the barrier to using these tools is now lower than the barrier to using them wisely. Oversight, regulation, and public understanding are not luxuries. They are prerequisites.